Skip to main content

Plasma epigenomics: A new liquid biopsy paradigm

Objective

Genomic DNA is packaged by histone proteins that carry a multitude of post-translational modifications, which reflect cellular transcriptional states. When cells die, fragmented chromatin retaining histone modifications is released to the circulation. Recently, we pioneered chromatin immunoprecipitation of cell-free nucleosomes carrying active chromatin marks followed by sequencing (cfChIP-seq). Our results show that cfChIP-seq provides multidimensional epigenetic information and that the plasma epigenome contains rich information about the identity and the transcriptional state of the originating cells.

Liquid biopsies already entered the clinical practice, yet current methodologies use them to assess genetic information. Our breakthrough methodology opens an unprecedented opportunity to delineate the transcriptional state of specific cell types and different pathologic states. Here we aim to translate plasma epigenomic information into medically relevant findings. The challenge is recovering the states of the cells represented in the circulation and relate these to pathological processes. Our working hypothesis is that this task is attainable by probabilistic modeling exploiting knowledge about epigenomics and transcription programs in health and disease. In this project we will assay plasma samples from multiple patient and donor cohorts to characterize the relation between tissue gene expression and circulating chromatin profiles, to recover the immune system status and chart how it changes with disease progression and response to treatment, and to monitor transplant patients for early detection of rejection.

Our extensive preliminary data, our expertise in probabilistic modeling and genomics and our collaborators’ access to relevant patient cohorts support the projects’ feasibility. Plasma epigenomics will open a new non-invasive window into tissue dynamics in living humans, beyond current liquid biopsy technologies, with far-reaching medical implications.

Call for proposal

ERC-2020-ADG
See other projects for this call

Funding Scheme

ERC-ADG - Advanced Grant

Host institution

THE HEBREW UNIVERSITY OF JERUSALEM
Address
Edmond J Safra Campus Givat Ram
91904 Jerusalem
Israel
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 962 500

Beneficiaries (1)

THE HEBREW UNIVERSITY OF JERUSALEM
Israel
EU contribution
€ 2 962 500
Address
Edmond J Safra Campus Givat Ram
91904 Jerusalem
Activity type
Higher or Secondary Education Establishments